Home » Healthcare » Cushing’s Syndrome and Acromegaly Treatment Market
Cushing’s Syndrome and Acromegaly Treatment Market By Treatment Type (Pharmacological Therapy, Surgical Treatment, Radiation Therapy); By Drug Class (Pharmacological) (Somatostatin Analogs, Steroidogenesis Inhibitors, Dopamine Agonists, Other Drugs); By End User (Hospitals, Specialty Clinics, Research Centers); By Geography – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Cushing’s Syndrome and Acromegaly Treatment Market Overview:
The Cushing’s Syndrome and Acromegaly Treatment Market size was valued at USD 1,762 million in 2024 and is anticipated to reach USD 2,486.58 million by 2032, at a CAGR of 4.4% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
Cushing’s Syndrome and Acromegaly Treatment Market Size 2024
USD 1,762 million
Cushing’s Syndrome and Acromegaly Treatment Market, CAGR
4.4%
Cushing’s Syndrome and Acromegaly Treatment Market Size 2032
USD 2,486.58 million
The Cushing’s Syndrome and Acromegaly Treatment market is led by prominent companies such as Novartis, Ipsen, Pfizer, Recordati, and Corcept Therapeutics. Novartis dominates with a broad hormonal therapy portfolio, while Ipsen and Pfizer strengthen their positions through established brands and global distribution networks. Recordati and Corcept focus on niche therapies for cortisol modulation and growth hormone control. Emerging players like Crinetics Pharmaceuticals and Camurus contribute to innovation through novel drug formulations. North America holds the leading regional position, capturing approximately 42% of the global market share in 2024. This dominance stems from advanced healthcare infrastructure, high diagnosis rates, and strong reimbursement systems. Europe follows with 31%, driven by universal healthcare access and active clinical networks. The competitive landscape continues to evolve as companies invest in R&D, expand indications, and pursue regional partnerships to reinforce their presence and address unmet needs in rare endocrine disorder treatments.
Cushing’s Syndrome and Acromegaly Treatment Market Insights
The Cushing’s Syndrome and Acromegaly Treatment market was valued at USD 1,762 million in 2024 and is projected to reach USD 2,486.58 million by 2032, growing at a CAGR of 4.4%.
Rising prevalence of pituitary and adrenal tumors, along with early diagnosis and specialist referrals, is driving long-term treatment demand across both pharmacological and surgical interventions.
Market trends show a shift toward non-surgical therapies, including long-acting injectables and oral formulations, with growing adoption of minimally invasive options improving patient adherence.
Novartis, Ipsen, Pfizer, and Corcept Therapeutics lead the competitive landscape, while new players like Crinetics and Camurus push innovation with next-gen hormone modulators.
North America holds the largest share at 42%, followed by Europe at 31%, while Asia Pacific is the fastest-growing region; pharmacological therapy dominates with over 65% share, and somatostatin analogs lead the drug class segment with nearly 48% share.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Cushing’s Syndrome and Acromegaly Treatment Market Segmentation Analysis:
By Treatment Type
Pharmacological therapy dominates the treatment type segment in the Cushing’s Syndrome and Acromegaly Treatment market, accounting for over 65% share in 2024. The demand is driven by the growing adoption of non-invasive, first-line treatments and the chronic nature of both conditions. Drug-based therapies offer long-term symptom control with fewer complications compared to surgery or radiation. The convenience of outpatient administration further supports preference for pharmacological options. Although surgical treatment remains essential in tumor-related cases, it is often reserved for severe or refractory stages. Radiation therapy is applied selectively, typically when drugs or surgery fail to deliver desired results.
For instance, Novartis’ Signifor (pasireotide) demonstrated mean urinary free cortisol reductions of 50 µg per 24 hours in controlled Cushing’s disease trials. Pfizer’s Somavert (pegvisomant) achieved normalized insulin-like growth factor-1 levels in more than 90 out of 100 treated acromegaly patients within one year of therapy.
By Drug Class (Pharmacological)
Somatostatin analogs lead the pharmacological drug class segment with a market share of nearly 48% in 2024. These agents are widely used in acromegaly management due to their proven efficacy in lowering growth hormone levels. Their extended-release formulations, such as octreotide LAR and lanreotide, improve patient adherence. Steroidogenesis inhibitors follow as the preferred class for Cushing’s syndrome, offering cortisol suppression without surgery. Dopamine agonists and other drugs serve niche roles, either as adjunctive therapies or in patients with mild symptoms. However, newer combination regimens and drug repurposing efforts are gradually expanding the scope for these smaller segments.
For instance, Ipsen’s Somatuline Depot (lanreotide) reduced growth hormone concentrations to below 2.5 ng/mL in over 70 treated acromegaly patients during pivotal studies. Recordati’s Isturisa (osilodrostat) lowered median cortisol levels from above 400 nmol/L to below 140 nmol/L within 12 weeks of treatment.
By End User
Hospitals hold the largest share in the end user segment, accounting for over 55% of total market revenue in 2024. Their dominance stems from access to multidisciplinary teams, surgical infrastructure, and advanced diagnostic tools for endocrine disorders. Specialty clinics are gaining traction, especially for follow-up care and pharmacological monitoring, due to shorter wait times and personalized approaches. Research centers, while limited in patient volume, contribute to clinical trials and innovative drug development. The increasing number of endocrine-focused hospital units and academic collaborations further reinforce hospitals’ central role in delivering comprehensive care.
Cushing’s Syndrome and Acromegaly Treatment Market Key Growth Drivers
Rising Prevalence of Endocrine Disorders Globally
The increasing global burden of endocrine disorders, particularly pituitary adenomas and adrenal tumors, continues to drive the Cushing’s Syndrome and Acromegaly Treatment market. Lifestyle-related risk factors such as obesity, hypertension, and long-term corticosteroid use are elevating the incidence of Cushing’s syndrome. Simultaneously, improved diagnostic screening is leading to earlier detection of acromegaly, often triggered by growth hormone-secreting pituitary tumors. As more patients are identified in both developed and developing nations, the demand for effective pharmacological and surgical interventions rises. According to recent clinical data, early-stage identification rates have improved by nearly 30% in tertiary hospitals across North America and Europe.
For instance, data hosted by the U.S. National Institutes of Health (NIH) estimate that approximately 25,000 people are living with acromegaly in the United States, with roughly 3,000 new cases diagnosed annually.
Advancements in Pharmacological Therapies and Drug Approvals
The development and approval of novel drugs with enhanced efficacy and reduced side effects are significantly propelling market growth. Pharmaceutical companies are investing in next-generation somatostatin analogs, cortisol inhibitors, and combination therapies to improve symptom control and patient outcomes. For instance, the approval of osilodrostat and relacorilant has expanded the treatment options for Cushing’s syndrome beyond surgery. Similarly, new formulations like oral octreotide and long-acting injectable drugs for acromegaly enhance convenience and adherence. Clinical trials are increasingly focusing on targeted therapies that modulate hormone pathways more precisely, reducing systemic toxicity. These innovations not only extend treatment to patients ineligible for surgery but also improve long-term disease management.
For instance, Recordati’s Isturisa (osilodrostat) reduced mean urinary free cortisol from above 400 nmol/L to below 150 nmol/L within 12 weeks in Phase III trials.
Strong Institutional Support and Multidisciplinary Care Models
Hospitals and specialty clinics have adopted integrated care models that support early diagnosis, treatment personalization, and long-term follow-up, enhancing patient outcomes and supporting market growth. Endocrinologists now work in tandem with neurosurgeons, oncologists, and radiologists to develop comprehensive care pathways for patients with Cushing’s syndrome and acromegaly. Governments and health systems are also backing rare disease management programs through funding, reimbursement policies, and clinical infrastructure. For example, several European nations have established endocrine tumor networks that facilitate referral, diagnosis, and treatment across centers of excellence. In the U.S., the Orphan Drug Act and related incentives help ensure that emerging therapies receive adequate market support. These frameworks reduce delays in treatment and improve continuity of care, especially for chronic cases.
Cushing’s Syndrome and Acromegaly Treatment Market Key Trends & Opportunities
Shift Toward Minimally Invasive and Non-Surgical Treatments
There is a clear market trend favoring pharmacological solutions over invasive surgery, especially in patients with high surgical risk or partial remission. Non-surgical approaches, including long-acting somatostatin analogs, steroidogenesis inhibitors, and dopamine agonists, are becoming standard initial treatments. Patients increasingly prefer outpatient or home-based injection regimens due to reduced recovery times and improved quality of life. This shift is also driven by improved drug tolerability, broader insurance coverage, and the availability of oral formulations in development stages. For instance, oral levoketoconazole and subcutaneous depot injections are offering new delivery methods. Hospitals are adapting care models to include endocrine day-care services, where patients receive diagnostic and therapeutic support without admission. This trend opens significant opportunities for drug manufacturers and specialty clinics focused on chronic endocrine care.
For instance, Ipsen’s Somatuline Depot delivers lanreotide at 120 mg every 28 days, successfully maintaining growth hormone suppression in clinical studies. Xeris Biopharma’s Recorlev (levoketoconazole) reduced mean urinary free cortisol (mUFC) from a baseline average of 671 nmol/day to a normalized level below 138 nmol/day (the upper limit of normal) in 30% of patients during pivotal late-stage trials.
Expansion in Emerging Markets Through Awareness and Access
Emerging economies in Asia Pacific, Latin America, and parts of the Middle East present significant untapped potential for market growth. Historically underdiagnosed in these regions, both Cushing’s syndrome and acromegaly are now receiving increased attention through public health campaigns and professional education. The growth of private healthcare networks and specialty hospitals has improved diagnostic capabilities, particularly MRI and hormone panel testing. Moreover, international partnerships are enabling access to off-patent drugs and biosimilars at affordable costs. Governments in countries like India, Brazil, and the UAE are also supporting rare disease programs, which include coverage for high-cost hormone therapies. As patient awareness grows and digital platforms disseminate information about symptoms and treatment, earlier medical consultation is encouraged. Pharmaceutical companies are responding by entering these markets through licensing agreements, local manufacturing, and tailored pricing strategies. This geographic expansion opens new revenue streams and reduces reliance on saturated North American and European markets.
Cushing’s Syndrome and Acromegaly Treatment Market Key Challenges
High Cost of Long-Term Treatment and Limited Reimbursement
The high cost of pharmacological therapies remains a major barrier, especially in lower- and middle-income countries. Somatostatin analogs and newer steroidogenesis inhibitors often require lifelong administration, pushing annual treatment costs beyond the reach of many patients. Insurance coverage for rare endocrine disorders varies significantly by region, and out-of-pocket expenses remain high in markets with fragmented reimbursement systems. Even in developed countries, insurance caps and pre-authorization processes delay treatment initiation. In countries with public health systems, expensive drugs often face delayed inclusion in national formularies. Furthermore, the need for regular biochemical testing, imaging, and specialist visits adds to the economic burden. This financial challenge affects patient adherence, treatment continuity, and long-term disease control.
Delayed Diagnosis and Underreporting of Cases
Both Cushing’s syndrome and acromegaly often present with vague, non-specific symptoms that mimic other conditions, leading to delayed diagnosis or misdiagnosis. Symptoms such as fatigue, weight gain, and hypertension are often attributed to lifestyle factors or common comorbidities. As a result, patients may go undiagnosed for several years, by which time the disease may have progressed significantly. In acromegaly, changes in facial features or extremity enlargement occur gradually, making early detection difficult without specialized assessment. Diagnostic delays are compounded by limited awareness among general practitioners and non-endocrine specialists. In rural or resource-limited settings, access to MRI imaging and hormonal assays remains inadequate. These gaps not only reduce the addressable market but also affect treatment efficacy, as early-stage intervention yields better outcomes.
Cushing’s Syndrome and Acromegaly Treatment Market Regional Analysis
North America
North America holds the largest share in the Cushing’s Syndrome and Acromegaly Treatment market, accounting for over 42% of global revenue in 2024. The region benefits from advanced diagnostic infrastructure, strong healthcare spending, and favorable reimbursement policies. High awareness among healthcare professionals and patients ensures early disease detection and timely intervention. The U.S. leads regional growth due to the presence of major pharmaceutical companies, ongoing clinical trials, and fast-track regulatory approvals. Canada supports market growth with national rare disease frameworks and specialty endocrine centers. Strong institutional care models and access to high-cost therapies further reinforce North America’s leadership.
Europe
Europe represents the second-largest market, contributing nearly 31% of global revenue in 2024. The region’s strength stems from a well-established network of specialty hospitals, universal healthcare access, and early adoption of innovative treatments. Countries such as Germany, France, and the UK dominate due to widespread insurance coverage and strong government support for orphan drugs. The European Medicines Agency (EMA) actively approves new therapies, aiding market expansion. Pan-European reference networks for rare endocrine diseases improve collaboration and patient referral. Continuous investment in research and public health initiatives strengthens Europe’s position as a leading region for treatment and clinical advancements.
Asia Pacific
Asia Pacific is emerging as the fastest-growing region, accounting for around 15% market share in 2024, with strong momentum expected through 2032. Growth is driven by rising healthcare investments, improved diagnostic capabilities, and expanding patient awareness in countries like China, India, Japan, and South Korea. Governments are supporting rare disease programs, including funding for hormonal testing and access to specialty drugs. The private healthcare sector is expanding endocrine specialty clinics across urban centers. Pharmaceutical players are entering regional markets through local partnerships, licensing deals, and biosimilar launches. These factors contribute to accelerated adoption of both surgical and pharmacological treatments.
Latin America
Latin America holds a modest share of around 7% in the Cushing’s Syndrome and Acromegaly Treatment market in 2024. Brazil and Mexico lead regional growth due to improving diagnostic access and increased specialist availability. However, challenges persist with delayed diagnoses and inconsistent insurance coverage. Efforts to boost awareness and strengthen tertiary care hospitals are gradually enhancing market conditions. Some nations have included rare endocrine diseases in public health agendas, enabling partial drug reimbursement. Local pharmaceutical manufacturing and international collaborations are also expanding access to affordable hormone therapies. The region presents growth potential as awareness and healthcare access improve.
Middle East & Africa
The Middle East & Africa region accounts for approximately 5% of the global market in 2024. Market development is uneven, with Gulf Cooperation Council (GCC) countries like the UAE and Saudi Arabia investing in endocrine care centers and rare disease programs. These nations benefit from strong government funding and partnerships with global pharmaceutical firms. In contrast, most Sub-Saharan countries face challenges related to limited access, underdiagnosis, and low awareness. Private healthcare providers are gradually expanding specialty services, especially in urban areas. Growth prospects depend on continued investment in diagnostics, physician training, and policy support for rare disease management.
Cushing’s Syndrome and Acromegaly Treatment Market Segmentations:
By Treatment Type
Pharmacological Therapy
Surgical Treatment
Radiation Therapy
By Drug Class (Pharmacological)
Somatostatin Analogs
Steroidogenesis Inhibitors
Dopamine Agonists
Other Drugs
By End User
Hospitals
Specialty Clinics
Research Centers
By Geography
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Cushing’s Syndrome and Acromegaly Treatment Market Competitive Landscape
The Cushing’s Syndrome and Acromegaly Treatment market features a moderately consolidated competitive landscape, led by key players such as Novartis, Pfizer, Ipsen, Recordati, and Corcept Therapeutics. These companies maintain dominance through strong product portfolios, global reach, and ongoing R&D in hormonal therapies. Novartis leads with established brands like Signifor and Sandostatin, while Ipsen drives growth with Somatuline Depot. Corcept Therapeutics specializes in cortisol modulation with Korlym, targeting Cushing’s syndrome specifically. Emerging players like Crinetics Pharmaceuticals and Camurus are advancing clinical-stage candidates that offer oral or long-acting alternatives to existing injectables. Strategic partnerships, licensing deals, and orphan drug designations support market entry and expansion. Competition is also intensifying through generics and biosimilars, particularly in developing regions. Companies focus on lifecycle management, label expansions, and improved delivery methods to retain market share. Innovation, pricing strategies, and regulatory approvals will continue to shape competitiveness over the forecast period.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In September 2025, Crinetics Pharmaceuticals received FDA approval for its nonpeptide somatostatin receptor type 2 (SST2) agonist, Palsonify (paltusotine), providing a first-line, once-daily oral treatment option for adults with acromegaly who were refractory to or unsuitable for surgery.
Report Coverage
The research report offers an in-depth analysis based on Treatment Type, Drug Class (Pharmacological), End-User andGeography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
The market will continue expanding as early diagnosis rates improve globally through better screening protocols.
Demand for pharmacological therapies will grow due to patient preference for non-invasive treatments.
Oral formulations and long-acting injectables will gain wider acceptance across outpatient care settings.
Emerging economies will drive future growth as awareness and specialty care access improve.
Companies will invest more in rare disease R&D, targeting hormone pathway-specific drug candidates.
Biosimilar entry and generic competition may reduce costs and improve treatment accessibility.
Digital tools for hormone monitoring and tele-endocrinology will enhance personalized care.
Strategic collaborations will increase between global pharmaceutical firms and regional healthcare providers.
Regulatory support for orphan drugs will accelerate approval and commercialization of novel therapies.
Market competition will intensify as new players introduce differentiated delivery technologies.
1. Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope
2. Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology
3. Executive Summary
4. Introduction
4.1. Overview
4.2. Key Industry Trends
5. Global Cushing’s Syndrome and Acromegaly Treatment Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast
9. Market Breakup by Region
9.1. North America
9.1.1. United States
9.1.1.1. Market Trends
9.1.1.2. Market Forecast
9.1.2. Canada
9.1.2.1. Market Trends
9.1.2.2. Market Forecast
9.2. Asia-Pacific
9.2.1. China
9.2.2. Japan
9.2.3. India
9.2.4. South Korea
9.2.5. Australia
9.2.6. Indonesia
9.2.7. Others
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. United Kingdom
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Others
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Others
9.5. Middle East and Africa
9.5.1. Market Trends
9.5.2. Market Breakup by Country
9.5.3. Market Forecast
12. Porter’s Five Forces Analysis
12.1. Overview
12.2. Bargaining Power of Buyers
12.3. Bargaining Power of Suppliers
12.4. Degree of Competition
12.5. Threat of New Entrants
12.6. Threat of Substitutes
The Urothelial Cancer Treatment Market size was valued at USD 2,887 million in 2024 and is anticipated to reach USD 13,531.47 million by 2032, at a CAGR of 21.3% during the forecast period.
The Manual Resuscitator Market size was valued at USD 640.4 million in 2024 and is anticipated to reach USD 1,036.2 million by 2032, growing at a CAGR of 6.2% during the forecast period.
The Airway Stent / Lung Stent Market is projected to grow from USD 91.45 million in 2025 to an estimated USD 151.82 million by 2032, with a compound annual growth rate (CAGR) of 7.5% from 2025 to 2032.
Liposuction market size was valued at USD 1,893 million in 2024 and is anticipated to reach USD 4,590.3 million by 2032, growing at a CAGR of 11.71% during the forecast period.
The IV Infusion Pump Accessories Market size was valued at USD 2,680 million in 2024 and is anticipated to reach USD 3,695.8 million by 2032, at a CAGR of 4.1% during the forecast period.
Insomnia Treatment Market size was valued at USD 3,497 million in 2024 and is anticipated to reach USD 5,135.88 million by 2032, at a CAGR of 4.92% during the forecast period.
The Irritable Bowel Syndrome with Constipation Drugs Market size was valued at USD 4,130 million in 2024 and is anticipated to reach USD 7,814.93 million by 2032, growing at a CAGR of 8.3% during the forecast period.
The AI in Clinical Trials Market is projected to grow from USD 2,538.43 million in 2025 to an estimated USD 12,240.4 million by 2032, registering a CAGR of 25.20% from 2025 to 2032.
The Adalimumab Drugs Market is projected to grow from USD 14,947.5 million in 2025 to an estimated USD 21,229.73 million by 2032, with a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.
The Global Acute Myeloid Leukemia (AML) Therapeutics Market size was valued at USD 1,933.8 million in 2018 to USD 3,349.2 million in 2024 and is anticipated to reach USD 6,823.4 million by 2032, at a CAGR of 9.33% during the forecast period
The Argatroban Market is projected to grow from USD 684.95 Million in 2024 to an estimated USD 911.10 Million by 2032, with a CAGR of 4.87% from 2024 to 2032.
The global Breast Cancer Core Needle Biopsy Market size was estimated at USD 923.45 million in 2025 and is expected to reach USD 1,256.69 million by 2032, growing at a CAGR of 4.5% from 2025 to 2032.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$5999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
